Patterns of clinical remission in select categories of juvenile idiopathic arthritis
- PMID: 16255044
- DOI: 10.1002/art.21389
Patterns of clinical remission in select categories of juvenile idiopathic arthritis
Abstract
Objective: To characterize disease activity patterns in a large cohort of children with juvenile idiopathic arthritis (JIA), by applying newly developed preliminary definitions of inactive disease, clinical remission on medication, and clinical remission off medication.
Methods: Children with persistent or extended oligoarthritis, polyarthritis (either rheumatoid factor [RF] positive or RF negative), or systemic JIA who had been followed up for a period of at least 4 years were evaluated for episodes of inactive disease, clinical remission on medication, and clinical remission off medication. Descriptive statistics, correlation analyses, and survival analyses were performed.
Results: Four hundred thirty-seven children met the criteria for review. Three hundred ninety-one patients (89%) experienced a total of 878 episodes of inactive disease, with a median episode length of 12.7 months. Two hundred twenty-eight episodes of inactive disease (26%) resulted in clinical remission off medication; it was equally as likely that episodes of inactive disease would or would not follow a period of clinical remission on medication. Thirty-six percent of episodes of clinical remission off medication persisted for at least 2 years, and only 6% of such episodes persisted for 5 years. RF-positive patients were the least likely to achieve clinical remission off medication (5%), and patients with persistent oligoarticular JIA were the most likely (68%). Among patients with persistent oligoarticular JIA, most of the disease course was characterized by inactive disease; in most other patients the majority of the disease course involved active disease.
Conclusion: Using newly developed preliminary criteria for inactive disease, clinical remission on medication, and clinical remission off medication, we observed that only one-fourth of 878 episodes of inactive disease resulted in clinical remission off medication during followup of at least 4 years. Only a small proportion of episodes of clinical remission off medication were sustained for >5 years. These results highlight the critical need for therapies that have the ability to induce sustained remission of JIA.
Similar articles
-
Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases.J Rheumatol. 2009 Jul;36(7):1532-5. doi: 10.3899/jrheum.080434. Epub 2009 Jun 1. J Rheumatol. 2009. PMID: 19487265
-
Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.J Rheumatol. 2006 Apr;33(4):789-95. Epub 2006 Feb 15. J Rheumatol. 2006. PMID: 16482643
-
Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study.Arthritis Rheum. 2009 Aug 15;61(8):1077-86. doi: 10.1002/art.24539. Arthritis Rheum. 2009. PMID: 19644903
-
Outcome following onset of juvenile idiopathic inflammatory arthritis: I. frequency of different outcomes.Rheumatology (Oxford). 2005 Aug;44(8):995-1001. doi: 10.1093/rheumatology/keh620. Epub 2005 Apr 12. Rheumatology (Oxford). 2005. PMID: 15827045 Review.
-
Measuring clinical response and remission in juvenile idiopathic arthritis.Curr Opin Rheumatol. 2007 Sep;19(5):471-6. doi: 10.1097/BOR.0b013e32825a6a68. Curr Opin Rheumatol. 2007. PMID: 17762613 Review.
Cited by
-
Advances in the treatment of polyarticular juvenile idiopathic arthritis.Curr Opin Rheumatol. 2015 Sep;27(5):505-10. doi: 10.1097/BOR.0000000000000206. Curr Opin Rheumatol. 2015. PMID: 26147756 Free PMC article. Review.
-
Current developments in the use of biomarkers for juvenile idiopathic arthritis.Curr Rheumatol Rep. 2014 Mar;16(3):406. doi: 10.1007/s11926-013-0406-3. Curr Rheumatol Rep. 2014. PMID: 24445961 Free PMC article. Review.
-
Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.Clin Rheumatol. 2009 Aug;28(8):985-8. doi: 10.1007/s10067-009-1162-7. Epub 2009 Mar 26. Clin Rheumatol. 2009. PMID: 19322622
-
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Nat Rev Rheumatol. 2014 Nov;10(11):682-90. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Nat Rev Rheumatol. 2014. PMID: 25112604 Review.
-
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.RMD Open. 2015 Apr 30;1(1):e000036. doi: 10.1136/rmdopen-2014-000036. eCollection 2015. RMD Open. 2015. PMID: 26509061 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous